Market Intelligence, Clinical Progress, and High-Purity Reagents for Alzheimer's Disease and Neurological Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BACE1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BACE1 Catalytic Domain (ECD) Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View BACE1 Products |
| Gene Delivery | BACE1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Preserves native membrane topology. | View BACE1 Products |
| Benchmark Ab | Anti-BACE1 Monoclonal (Research Grade). Recombinant positive control for Western/IP. Sequence-defined. | View BACE1 Products |
| Validator | BACE1 siRNA Set. For knockdown verification and specificity control. | View BACE1 Products |
| Substrate / Partner | APP (Amyloid Precursor Protein). Biological substrate for enzymatic assays. | View APP Products |
| Selectivity Control | BACE2 (Beta-Secretase 2). Close homolog for off-target screening (52% homology). Critical for counter-screening to prevent pigmentation loss and other toxicities. | View BACE2 Products |
| Pathway Component | PSEN1 (Presenilin 1). γ-Secretase component for combination pathway studies. | View PSEN1 Products |
| Synergistic Target | TREM2. Neuroinflammation pathway target for combination therapies. | View TREM2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BACE1 vs BACE2 Selectivity (Off-target liability) | Human BACE1 and BACE2 ortholog proteins available with >95% purity; Sequence Verified; Ideal for side-by-side SPR or FRET assays. |
| Substrate Specificity (APP vs Neuregulin) | Full-length BACE1 Lentivirus for physiologically relevant membrane context; Native glycosylation preserves authentic cleavage profiles. |
| False Positives in Cellular Assays | Validated BACE1 siRNA included for target-specificity verification; Catalytic-dead mutant controls available. |
| Cross-species Translation (Mouse to Human) | Human/Mouse/Cyno ortholog protein panel with identical production standards (HEK293 platform). |
| Native Glycosylation Preservation | Mammalian host (HEK293) expression ensures native post-translational modifications, crucial for protease structural integrity. |
| Lack of Cellular Controls | Lentivirus Premade Particles enable stable, biologically relevant neural cell line construction. |
Live BACE1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The BACE1 inhibitor landscape has shifted dramatically following Phase III setbacks of first-generation orthosteric inhibitors (verubecestat, atabecestat, lanabecestat, umibecestat) due to cognitive side effects and lack of efficacy in late-stage Alzheimer's Disease. However, BACE1 remains a critical mechanistic node for next-generation approaches: allosteric modulators, substrate-selective cleavage regulators, and targeted protein degradation (PROTAC/LYTAC). Key focus areas include partial/modulated inhibition to reduce Aβ without complete enzymatic blockade; prevention trials in autosomal-dominant AD and Down syndrome; non-AD indications such as epilepsy and myelination disorders; and exploration of brain-delivery systems. Academic and translational labs continue to demand high-fidelity BACE1 reagents for mechanistic studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor/Modulator (Orthosteric & Allosteric) | Biogen, Eisai, Novartis, Merck, Eli Lilly, Academic Consortia | Alzheimer's Disease (Prevention), Down Syndrome, Epilepsy, Peripheral Neuropathy | Enzymatic & Cell-based Assay (Need high-purity Catalytic Domain with native glycosylation and full-length Lentivirus for membrane integrity) |
| PROTAC / Degrader | Emerging Biotechs, Academic Consortia | Alzheimer's Disease, Neurodegeneration | Degradation Tracking (Need full-length BACE1 Lentivirus for stable cell line construction and knockdown) |
| Substrate-Selective Modulator | Academic Consortiums | Alzheimer's Disease | Competition Binding Assay (Need APP & NRG1 recombinant substrates for specificity profiling) |
| Antibody / Biologic | Denali Therapeutics, Biogen, Preclinical | Alzheimer's Disease (Alternative mechanism) | BBB Penetrance & Binding (Need high-purity ECD-Fc for SPR/BLI) |
| Peptide-Based Inhibitor | Research Phase | Neurodegenerative Diseases | Competition Binding Assay (Need ECD-Fc for SPR/BLI) |
| Neurotoxicology / Mechanism Studies | Academic Institutes | Demyelination / NRG1 Pathology | siRNA Knockdown + ECD Protein for rescue experiments |